Hempacco Co., Inc.: Nasdaq/NYSE listing notice — Hempacco receives Nasdaq notice of non-compliance with audit committee requirement

Hempacco Co., Inc.

Nasdaq notified Hempacco on Nov 15, 2023 of non-compliance with Listing Rule 5605.
Non-compliance triggered by Oct 26, 2023 resignation of director Dr. Stuart Titus.
Cure period extends to next annual meeting or Oct 26, 2024 (or Apr 23, 2024 if earlier).
Company has identified two prospective independent directors to fill audit committee vacancies.
Non-compliance does not result in immediate delisting; company expects to cure within period.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Hempacco Co., Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605

Exact text from the filing

November 15, 2023, Hempacco Co., Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not in compliance with Nasdaq’s audit committee requirements as set forth in Listing Rule 5605 (the “ Audit Committee Requirement ”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq listing rules require the Company to have an audit committee comprised of at least three independent directors, and as of Octo

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001477932-23-008754

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.